COMPARISON
Degarelix vs Ganirelix
5 attributes held for at least one of the two. 4 differ. Each value carries the register it came from and the date that register was read.
Answer
Degarelix is authorised or registered in 8 and Ganirelix in 10 of the 10 registers read. Degarelix: highest phase Phase 3 (7 phase 3 trials, 0 with posted results). Ganirelix: highest phase Phase 4 (after approval). 2 registered trials include both.
States no view on which is preferable, safer or more effective. Not medical advice.
| Degarelix | Ganirelix | |
|---|---|---|
| Registered trials differs | 187 clinicaltrials.gov · 2026-10-03 | 108 clinicaltrials.gov · 2026-10-03 |
| FDA label differs | FDA-approved: FIRMAGON openfda · 2026-10-03T17:23:44.062Z | FDA-approved: Ganirelix Acetate openfda · 2026-10-03T17:23:44.062Z |
| EU authorisation | Authorised ema · 2026-10-03 | Authorised ema · 2026-10-03 |
| EU authorised on differs | 2009-02-17 ema · 2026-10-03 | 2000-05-16 ema · 2026-10-03 |
| ATC code differs | L02BX02 ema · 2026-10-03 | H01CC01 ema · 2026-10-03 |
SIDE EFFECTS
Most common side effects, each beside its own placebo
| Side effect | Degarelix | placebo | Ganirelix | placebo |
|---|---|---|---|---|
| Injection site erythema | 14.1% | 0.0% | - | - |
| Injection site pain | 8.4% | 0.0% | - | - |
| Injection site induration | 7.8% | 0.0% | - | - |
| Hypertension | 6.2% | 7.1% | - | - |
| Back pain | 4.9% | 9.2% | - | - |
| Prostatic specific antigen increased | 4.9% | 6.1% | - | - |
| Nasopharyngitis | 4.6% | 5.1% | - | - |
| Hot flush | 4.3% | 0.8% | - | - |
| Influenza | 4.2% | 5.1% | - | - |
| Headache | 2.9% | 5.1% | - | - |
Trial register Degarelix: 2 placebo-controlled trials; Ganirelix: 0. Each peptide is compared with placebo in its own trials, not with the other: a dash means the event is not in that peptide's top list. Degarelix side effects · Ganirelix side effects
LEGAL STATUS
Approval in each country read
| Country | Degarelix | Ganirelix | Register |
|---|---|---|---|
| United States | FDA-approved | FDA-approved | Regulator FDA |
| European Union | Authorised | Authorised | Regulator EMA |
| United Kingdom | Authorised | Authorised | Regulator MHRA |
| Canada | Authorised | Authorised | Regulator Health Canada |
| Australia | Registered | Registered | Regulator TGA |
| Switzerland | Authorised | Authorised | Regulator Swissmedic |
| Brazil | Registado | Registado | Regulator ANVISA |
| Serbia | Not on the register | Authorised | Regulator ALIMS |
| Singapore | Registered | Registered | Regulator HSA |
| Turkey | Not on the register | Ruhsatli | Regulator TITCK |
HEAD TO HEAD
2 registered trials include both
| NCT03861715 | Single Follicular Dexarelix for LH Suppression During Ovarian Stimulation in Oocyte Donors. UNKNOWN · updated 2020-10-08 |
|---|---|
| NCT00434122 | Exploratory Study Assessing Synchronisation of Egg Sacs With Degarelix COMPLETED · updated 2011-06-02 |
Values reproduce public registers on the dates shown. This comparison states no view on which compound is preferable, safer or more effective. Not medical, legal or regulatory advice.
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.